Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 125

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 125
---
, 1,817,017 shares of the Company’s common stock at a purchase price per share of $1.175. In addition,
    in a concurrent private placement, the Company also issued to the purchasers in the November 2024 Offering unregistered warrants
    to purchase 1,817,017 shares of the Company’s common stock (the “November 2024 Warrants”). The November 2024 Warrants
    are immediately exercisable at an exercise price of $1.05 per share and expire five years from the date of issuance. The total net
    proceeds were approximately $1.8 million, after deducting placement agent and other offering expenses in the amount of approximately
    $0.35 million. In December 2024, the Company filed a registration statement to register the resale by the investors of the shares
    of common stock issuable upon exercise of the November 2024 Warrants. The registration statement was declared effective on December
    31, 2024. In addition, in connection with the November 2024 Offering, the Company issued to the placement agent and its designees
    warrants to purchase an aggregate of 124,212 shares of common stock at an exercise price of $1.3125. The placement agent warrants
    are exercisable six months from the date of issuance and expire on the fifth anniversary of the issue date. The fair value of a warrant
    to purchase one share of common stock that was issued to the placement agent was $0.93.

    e.
    On January 16, 2025, the
    Company completed a private placement offering pursuant to which the Company sold and issued to certain investors an aggregate of
    2,109,383 shares of common stock and warrants to purchase 2,109,383 shares of common stock (the “January 2025 Warrants”).
    The shares and January 2025 Warrants were sold on a combined basis for consideration of $1.065 for one share and one January 2025
    Warrant. The January 2025 Warrants are immediately exercisable at an exercise price of $0.94 per share and expire five years from
    the date of issuance. The total net proceeds were approximately $2.0 million, after deducting placement agent and other offering
    expenses in the amount of approximately $0.25 million. In February 2025, the Company filed a registration statement to register the
    resale by the investors